ARCHIVES

In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs

This article is from The Cancer Letter archive.

Vol. 24 No. 45 | November 27, 1998

Download PDF Visit The Full Archive

Related Articles

CCOPs Payline Set In Low 220s Fr Now; 45 To Be Funded

May 15, 1987

“Alternative” Is Misleading Term, President’s Cancer Panel Writes To Healy

February 5, 1993

NCI Advisors To Gain Increased Responsibility For Concept, Technical Merit Review Of Contracts

December 19, 1980

NCI Treatment Division To Recompete $10 Million In Resource Contracts; Board Okays New Projects

November 12, 1976

FDA Staff Failed To Explain Approval Standards, Correct Misconceptions.

April 13, 2007

NCI To Ask HCFA to Launch Pilot Clinical Trials Program

March 22, 1996